Recent 8-K filings for CRMD

• May 14, 2026, 7:34 AM ET earnings materiality 0.85 positive item 2.02item 9.01

  CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance

  Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.

• April 27, 2026, 7:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis

  Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.

• March 6, 2026, 6:59 PM ET other material materiality 0.70 neutral item 7.01item 9.01

  CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M

  Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.

• March 5, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance

  Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.

• January 8, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 5.02item 8.01item 9.01

  CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed

  Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).

• November 12, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  CorMedix reports Q3 net income of $108.6M, raises FY 2025 pro forma revenue guidance to $390-410M

  Net revenue of $104.3M (pro forma $130.8M) driven by DefenCath sales of $88.8M; diluted EPS $1.26.

• October 20, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M

  Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.

• September 30, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 9.01

  CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M

  Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.

• September 2, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 2.01item 3.02item 5.02item 7.01item 9.01 ◈ M&A Transactions

  CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance

  Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.

• August 12, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 3.02item 9.01

  CorMedix closes $150M convertible note offering due 2030 at 4.00% interest

  Issued $150M aggregate principal of 4.00% Convertible Senior Notes due 2030 in a private placement.

• August 7, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 2.02item 3.02item 7.01item 8.01item 9.01

  CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M

  Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.

• June 30, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  CorMedix closes $85M public offering of common stock, net proceeds $82.2M

  Closed public offering of 6,604,507 shares at gross proceeds ~$85M.

• June 25, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  CorMedix shareholders elect all 7 director nominees, approve say-on-pay and auditor ratification

  Directors elected: Dillione 15.6M votes, Duncan 17.6M, Dunton 17.0M, Kaplan 14.2M, Lefkowitz 17.4M, Stewart 15.8M, Todisco 18.3M.

• June 23, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients

  LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.

• May 6, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end

  Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.

• April 22, 2025, 7:59 PM ET other material materiality 0.25 neutral item 4.01item 9.01

  CorMedix engages CBIZ CPAs as new auditor; Marcum resigns after acquisition

  Marcum LLP resigned April 17, 2025; CBIZ CPAs engaged immediately for FY2025, approved by Audit Committee.

• April 8, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M

  Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.

• March 25, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M

  Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.

• January 7, 2025, 6:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M

  Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.

• November 25, 2024, 6:59 PM ET other materiality 0.35 neutral item 5.02item 5.07item 9.01

  CorMedix shareholders approve stock plan amendment increasing authorized shares; all director nominees elected

  Plan amendment to increase share authorization under 2019 Omnibus Stock Incentive Plan approved with 16.5M FOR, 2.8M AGAINST, 0.8M abstain.

• October 30, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics

  Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.

• August 14, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M

  Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.

• May 9, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024

  Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.

• March 12, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024

  Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.72 · Most common event earnings

15 positive 0 negative 9 neutral

source · CRMD on sec.gov